May 19, 2023, CTI BioPharma Corp. (NASDAQ: CTIC) trading session started at the price of $8.93, that was 0.22% jump from the session before. During the day, the shares moved up to $8.94 and dropped to $8.92 before settling in for the closing price of $8.92. A 52-week range for CTIC has been $4.01 – $8.96.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 16.50% over the last five years. When this article was written, the company’s average yearly earnings per share was at 25.40%. With a float of $125.91 million, this company’s outstanding shares have now reached $131.57 million.
The firm has a total of 128 workers. Let’s measure their productivity. In terms of profitability, gross margin is +93.12, operating margin of -128.82, and the pretax margin is -172.37.
CTI BioPharma Corp. (CTIC) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward CTI BioPharma Corp. stocks. The insider ownership of CTI BioPharma Corp. is 5.50%, while institutional ownership is 79.30%. The most recent insider transaction that took place on Jan 24, was worth 600,000. In this transaction EVP & Chief Commercial Officer of this company sold 100,000 shares at a rate of $6.00, taking the stock ownership to the 3,565 shares. Before that another transaction happened on Jan 24, when Company’s President and CEO sold 85,317 for $6.00, making the entire transaction worth $511,923. This insider now owns 29,440 shares in total.
CTI BioPharma Corp. (CTIC) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 3/30/2023, it has been observed that the corporation posted -$0.1 earnings per share (EPS) during the time that was better than consensus figure (set at -$0.12) by $0.02. This company achieved a net margin of -172.37. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.40% per share during the next fiscal year.
CTI BioPharma Corp. (NASDAQ: CTIC) Trading Performance Indicators
You can see what CTI BioPharma Corp. (CTIC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.30. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.52.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.58, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach 0.33 in one year’s time.
Technical Analysis of CTI BioPharma Corp. (CTIC)
Analysing the last 5-days average volume posted by the [CTI BioPharma Corp., CTIC], we can find that recorded value of 7.28 million was better than the volume posted last year of 4.74 million. As of the previous 9 days, the stock’s Stochastic %D was 99.29%. Additionally, its Average True Range was 0.32.
During the past 100 days, CTI BioPharma Corp.’s (CTIC) raw stochastic average was set at 99.60%, which indicates a significant increase from 99.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 252.66% in the past 14 days, which was higher than the 108.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.27, while its 200-day Moving Average is $5.54. Now, the first resistance to watch is $8.95. This is followed by the second major resistance level at $8.95. The third major resistance level sits at $8.97. If the price goes on to break the first support level at $8.93, it is likely to go to the next support level at $8.91. Should the price break the second support level, the third support level stands at $8.91.
CTI BioPharma Corp. (NASDAQ: CTIC) Key Stats
There are 131,880K outstanding shares of the company, which has a market capitalization of 1.18 billion. As of now, sales total 53,950 K while income totals -92,990 K. Its latest quarter income was 21,080 K while its last quarter net income were -17,460 K.
